Tadalafil Cohort Shows 0.85 HR for All-Cause Mortality in ED Patients

NPR coverage on 17 August 2026 summarized claims that PDE5 inhibition via tadalafil may extend lifespan through vascular mechanisms. The piece relied on existing cohort studies without presenting new trial data. No primary endpoint for longevity has been registered at ClinicalTrials.gov for this indication.

Published cohorts, including a 2023 JAMA Internal Medicine analysis of 1.2 million men, reported lower cardiovascular events among consistent tadalafil users. These findings remain subject to healthy-user bias: men receiving and adhering to ED prescriptions differ systematically in baseline health-seeking behavior and comorbidities. Propensity-score adjustments in the studies do not eliminate residual confounding.

Operationally, any longevity signal would require prospective randomization with mortality as primary endpoint and minimum five-year follow-up. Current FDA labeling for tadalafil covers only erectile dysfunction and pulmonary arterial hypertension. Off-label longevity use lacks both efficacy confirmation and safety data at population scale.

Next regulatory action hinges on whether any sponsor files an investigational new drug application for a dedicated longevity trial by 2027. Absent such filing, label expansion remains improbable.